Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes

Journal of Diabetes and its Complications

Volumn 27, Issue 2, 2013, Pages 177-183

  Fonseca, Vivian ^a   Staels, Bart ^b   Morgan II, Jerry D ^c   Shentu, Yue ^c   Golm, Gregory T ^c   Johnson Levonas, Amy O ^c   Kaufman, Keith D ^c   Goldstein, Barry J ^c   Steinberg, Helmut ^c  

^a TULANE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIV LILLE   (France)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

DPP 4 inhibitor; glycemic control; hemoglobin A1c; hyperglycemia; sitagliptin

Indexed keywords

C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PIOGLITAZONE; PLACEBO; PROINSULIN; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INFECTION; INFESTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; LOST TO FOLLOW-UP; METFORMIN; MIDDLE AGED; PATIENT DROPOUTS; PPAR GAMMA; PYRAZINES; THIAZOLIDINEDIONES; TRIAZOLES; YOUNG ADULT;

EID: 84875221492     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2012.09.007     Document Type: Article

References (15)

1. American Diabetes Association Standards of medical care in diabetes - 2012 Diabetes Care 35 Suppl 1 2012 S11 S63
2. P. Aschner, M.S. Kipnes, J.K. Lunceford, M. Sanchez, C. Mickel, and D.E. Williams-Herman Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes Diabetes Care 29 2006 2632 2637
3. Z.T. Bloomgarden, R. Dodis, C.M. Viscoli, E.S. Holmboe, and S.E. Inzucchi Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: A meta-regression analysis Diabetes Care 29 2006 2137 2139
4. B. Cariou, B. Charbonnel, and B. Staels Thiazolidinediones and PPAR gamma agonists: Time for a reassessment Trends in Endocrinology and Metabolism 23 2012 205 215
5. R.A. DeFronzo Banting Lecture. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus Diabetes 58 2009 773 795
6. G.A. Herman, A. Bergman, C. Stevens, P. Kotey, B. Yi, and P. Zhao Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes The Journal of Clinical Endocrinology and Metabolism 91 2006 4612 4619
7. G.A. Herman, C. Stevens, K. Van Dyck, A. Bergman, B. Yi, and M. De Smet Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses Clinical Pharmacology and Therapeutics 78 2005 675 688
8. J.J. Holst, and J. Gromada Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans American Journal of Physiology. Endocrinology and Metabolism 287 2004 E199 E206
9. R.S. Hundal, and S.E. Inzucchi Metformin: New understandings, new uses Drugs 63 2003 1879 1894
10. I. Idris, and R. Donnelly Dipeptidyl peptidase-IV inhibitors: A major new class of oral antidiabetic drug Diabetes, Obesity & Metabolism 9 2007 153 165
11. D. Kim, L. Wang, M. Beconi, G.J. Eiermann, M.H. Fisher, and H. He (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H) -yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes Journal of Medicinal Chemistry 48 2005 141 151
12. A.J. Krentz, and C.J. Bailey Oral antidiabetic agents: Current role in type 2 diabetes mellitus Drugs 65 2005 385 411
13. D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, and R.C. Turner Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 1985 412 419
14. O. Miettinen, and M. Nurminen Comparative analysis of two rates Statistics in Medicine 4 1985 213 226
15. R.C. Turner, C.A. Cull, V. Frighi, and R.R. Holman Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group JAMA: The Journal of the American Medical Association 281 1999 2005 2012